Allan D Levi

US Patent:

20190055515, Feb 21, 2019

Filed:

Feb 24, 2017

Appl. No.:

16/078537

Inventors:

- Miami FL, US
Gagani Athauda - Miami FL, US
Mary Bunge - Miami FL, US
James Guest - Miami FL, US
Allan Levi - Miami FL, US
Damien Pearse - Miami FL, US
Patrick Wood - Miami FL, US

International Classification:

C12N 5/079
A61K 35/30
A61L 27/38

Abstract:

The invention provides a method of producing a population of human Schwann cells. The method comprises (a) incubating human fascicles with one or more mitogens for a priming period of three to fourteen days to produce primed fascicles, (b) incubating the primed fascicles with one or more tissue dissociation enzymes to produce primed Schwann cells, (c) culturing the primed Schwann cells at an initial Po density for a period of time to achieve no greater than 90% confluence, (d) expanding the population of Schwann cells by culturing the Schwann cells at an initial passage density for a period of time to achieve no greater than 90% confluence for at least two passages, and harvesting the population of human Schwann cells. The invention further provides an isolated population of Schwann cells obtained by the method described herein. In various aspects of the invention, the isolated population is provided in a composition.

US Patent:

20170003303, Jan 5, 2017

Filed:

Jul 20, 2016

Appl. No.:

15/214868

Inventors:

- Miami FL, US
W. Dalton Dietrich - Miami FL, US
Juan Pablo de Rivero Vaccari - Miami FL, US
Stephanie Adamczak - Miami FL, US
M. Ross Bullock - Miami Beach FL, US
Allan Levi - Key Biscayne FL, US
Michael Y. Wang - North Miami FL, US

International Classification:

G01N 33/68

Abstract:

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the serverity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilition efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.

US Patent:

20150185232, Jul 2, 2015

Filed:

Feb 6, 2013

Appl. No.:

14/376383

Inventors:

- MIAMI FL, US
W. Dalton Dietrich - Miami FL, US
Juan Pablo de Rivero Vaccari - Miami FL, US
Stephanie Adamczak - Miami FL, US
M. Ross Bullock - Miami Beach FL, US
Allan Levi - Key Biscayne FL, US
Michael Y. Wang - North Miami FL, US

International Classification:

G01N 33/68
A61F 7/00

Abstract:

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.

Address:

175 Hbr Dr, Key Biscayne, FL 33149

VIN:

WP0CA299X7S765660

Make:

PORSCHE

Model:

911

Year:

2007